LivaNova PLC
NASDAQ:LIVN
LivaNova PLC
NASDAQ:LIVN
Price:
62.62 USD
12.32%
Updated:
May 2, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
34.3
Current
25.6
Median
12.5
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=34.3
Enterprise Value
/
3.7B
EBITDA
107.2m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| UK |
|
LivaNova PLC
NASDAQ:LIVN
|
3.4B USD | 34.3 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
183B USD | 19.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
131.6B USD | 54.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.8B USD | 24 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.8B USD | 13.7 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
104.8B USD | 30.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.9B USD | 18.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
57.2B EUR | 18.2 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
368.4B CNY | 28.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
51.1B USD | 26.2 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49.6B USD | 58 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
15
2-Years Forward
EV/EBITDA
13.7
3-Years Forward
EV/EBITDA
12.5
You don't have any saved screeners yet
